Mutation profiles of follicular thyroid tumors by targeted sequencing

Diagnostic Pathology

Table 3 Association of TERTp and H/N/K-RAS mutations with clinicopathological featurs in 53 FTC patients

Variations	H/N/K-RAS- TERTp-	H/N/K-RAS+ TERTp-	H/N/K-RAS- TERTp+	H/N/K-RAS+ TERTp+	P
Cases	30	10	6	7
Sex					0.406
Male	8 (27)	2 (20)	2 (33)	4 (57)
Female	22 (73)	8 (80)	4 (67)	3 (43)
Age, years					0.013
Median ± SD	43 ± 3	33 ± 5	59 ± 2	66 ± 3	0.013
Tumor size (cm)					0.764
<2.0	8 (27)	3 (30)	3 (50)	3 (43)
2.0–4.0	16 (53)	5 (50)	1 (17)	3 (43)
>4.0	6 (20)	2 (20)	2 (33)	1 (14)
Lymph node metastasis					0.271
Yes	2 (7)	1 (10)	0	2 (29)
No	28 (93)	9 (90)	6 (100)	5 (71)
Distant metastasis					0.057
Yes	0	0	1 (17)	1 (14)
No	30 (100)	10 (100)	5 (83)	6 (86)
AJCC Stage					0.015
I	27 (90)	10 (100)	4 (67)	3 (43)
II	3 (10)	0	2 (33)	2 (29)
III	0	0	0	1 (14)
IV	0	0	0	1 (14)
Histologic type					0.681
Minimally invasive	16 (53)	5 (50)	2 (33)	2 (28)
Encapsulated angioinvasive	7 (23)	4 (40)	2 (33)	2 (28)
Widely invasive	7 (23)	1 (10)	2 (33)	3 (43)
Disease recurrence/persistence ^a					0.026
Yes	2 (7)	1 (10)	2 (29)	3 (50)
No	28 (93)	9 (90)	4 (71)	3 (50)

^a, fifty-two patients were available to evaluate the disease recurrence/persistence status, the other patient was lost to follow-up
Abbreviations: TERTp, TERT promoter, FTC follicular thyroid carcinoma, AJCC American Joint Committee on Cancer, 8th edition staging, P P-value, median ± SD median ± standard deviation

ISSN: 1746-1596